Editors for Cancer Biology
Senior editors
-
Utpal Banerjee
University of California, Los Angeles, United States
Utpal Banerjee is the Irving and Jean Stone Professor and Chair of the Department of Molecular, Cell and Developmental Biology at the University of California, Los Angeles, with a joint appointment in the Department of Biological Chemistry at the David Geffen School of Medicine. He also serves as Co-Director of the Broad Stem Cell Research Center and as Director of the UCLA Interdepartmental Minor in Biomedical Research. He is a member of UCLA’s Jonsson Comprehensive Cancer Center and is affiliated with the Brain Research Institute and the Neuroscience Graduate Program.
Banerjee’s laboratory has worked on several oncogenic and metabolic signals that are important in development and disease. The lab studies the effects of systemic signals on the maintenance of blood progenitors in Drosophila, and the role of metabolic pathways in the control of proliferation and differentiation in the preimplantation mouse embryo.
- Expertise
- Developmental Biology
- Stem Cells and Regenerative Medicine
- Cancer Biology
- Research focus
- haematopoiesis
- cancer biology
- Experimental organism
- D. melanogaster
- mouse
-
Yamini Dalal
National Cancer Institute, United States
Yamini Dalal did her graduate work on chromatin structure with Arnie Stein and Minou Bina at Purdue University (PhD, 2003), and her postdoctoral research on centromeres with Steve Henikoff at the Fred Hutch Cancer Research Center (2007). She is currently a Senior Investigator leading the Chromosome Structure and Epigenetics Mechanism Unit within the Laboratory of Receptor Biology and Gene Expression at the Center for Cancer Research of the NCI/NIH in Bethesda. Her lab focuses on histones, which package the entirety of the human genome into chromatin. Using a combination of chromatin biochemistry, computational modelling, atomic force microscopy (AFM), genetics, genomics and cell biology, Dr. Dalal and colleagues are investigating whether chromatin adopts alternate structural conformations in cancer cells, the functional consequences of large-scale chromosomal alterations upon the cancer epigenome, and identifying small molecules which can target these structures or processes.
- Expertise
- Cancer Biology
- Chromosomes and Gene Expression
- Genetics and Genomics
- Research focus
- chromatin
- centromeres
- chromosomes
- mitosis
- chromosome cancer biology
- histone variants
- nucleosomes
- histones
- Experimental organism
- human
- mouse
- Competing interests statement
- Dr. Dalal is serving as Deputy Editor of eLife in her personal capacity as a chromosome biology expert with a deep interest in molecular and cellular biology, not as a representative of the NIH.
-
Wafik S El-Deiry
Brown University, United States
Wafik El-Deiry, MD, PhD, FACP is Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Director, Cancer Center at Brown University, and Director of the Joint Program in Cancer Biology at Brown and Lifespan. He is a Professor of Pathology and Laboratory Medicine, Professor of Medical Science, and Mencoff Family University Professor at Brown. He sees patients in his weekly clinic at Rhode Island Hospital focused on care of patients with colorectal cancer and participates in clinical trials based on his laboratory’s research on novel therapeutics. He previously served as Deputy Director for Translational Research, co-Leader of the Molecular Therapeutics Program, Professor of Oncology, and the William Wikoff Smith Endowed Chair in Cancer Research at Fox Chase Cancer Center. From 2010 through 2014 Dr El-Deiry was the Rose Dunlap Professor of Medicine and Chief of Hematology-Oncology at Penn State. In 2009, El-Deiry became an American Cancer Society Research Professor. He was previously a tenured Professor of Medicine (Hematology-Oncology), Genetics, and Pharmacology at University of Pennsylvania, co-Leader of the Radiobiology and Imaging Program at the Abramson Cancer Center and Associate Director for Physician-Scientist Training in Hematology-Oncology when he left Penn in 2010. He earned MD/PhD degrees from University of Miami School of Medicine and completed internal medicine residency and medical oncology fellowship at the Johns Hopkins Hospital and the Johns Hopkins Oncology Center. As a practicing academic Oncologist, his scientific interest and expertise is in cell death, drug resistance in cancer and drug discovery and development. El-Deiry founded two companies, Oncoceutics, Inc. and p53-Therapeutics, Inc.
El-Deiry discovered p21(WAF1) as a p53 target gene, universal cell cycle inhibitor, and tumor suppressor gene that for the first time explained the mammalian cell stress response. He discovered TRAIL receptor DR5 and its regulation by p53. TRAIL is part of the host immune system that suppresses cancer and its metastases. His lab created a knock-out mouse for TRAIL receptor DR5 and this mouse is tumor prone and develops an inflammatory syndrome in the lungs and gut after sub-lethal irradiation. He identified c-Myc as a major determinant of TRAIL sensitivity and demonstrated synergy between TRAIL therapy and multi-kinase inhibitor sorafenib. Building on his prior accomplishments, El-Deiry discovered ONC201/TIC10 as a first-in-class TRAIL pathway inducer that is orally bioavailable and crosses the blood-brain barrier to treat brain tumors. TRAIL and Foxo3a are required for the anti-tumor effect of ONC201 through dual blockade of ERK and Akt kinases that promotes the nuclear translocation of the Foxo3a transcription factor which directly regulates the TRAIL gene. Data from El-Deiry’s lab identified that ONC201 induces TRAIL receptor DR5 through an integrated stress response involving ATF4 and CHOP transcription factors. Patients with among the most aggressive gliomas (H3K27M mutant DIPG) have had exceptional responses to ONC201.
As a physician-scientist, Dr El-Deiry has worked to bring new discoveries to the clinic. He is committed in the next phase of his career to unraveling the mechanisms involved in p53 pathway restoration by candidate therapeutics his lab has discovered. This is exciting as he is defining a novel class of anti-cancer drugs with p53 pathway restoration and S-phase checkpoint targeting and recognizing ATF4 as a major transcription factor mechanism for p53 pathway restoration in p53-null or p53 mutant tumor cells. He is establishing transcriptomic and proteomic data sets with chemotherapy that acts through p53, and with novel small molecules that restore the p53 pathway in p53-deficient or mutant p53 expressing cells. He is exploiting medicinal chemistry and organoid technologies to perform his translational science that is leading to clinical trials some of which he leads. Dr El-Deiry conducts basic and translational clinical oncology therapeutics research through funded NIH grants, Foundations and industry. He is a member of the ASCI, AAP, Past President of the Interurban Clinical Club, previous Chair of ASCO’s Tumor Biology Track, and past Chair of an NIH Study Section on Cancer Therapeutics. Dr El-Deiry has trained many students and post-doctoral fellows, physician-scientists, and continues to mentor junior scientists and faculty in basic and translational cancer research.
- Expertise
- Medicine
- Cancer Biology
- Research focus
- cancer
- tumor suppressor genes
- colorectal cancer
- p53 pathway
- cell death
- medical oncology
- drug development
- drug discovery
- p21(WAF1)
- ONC201/TIC10
- physician-scientist issues
- Experimental organism
- human
- mouse
- Competing interests statement
- Dr El-Deiry receives funding from the NIH/NCI, the Warren Alpert Foundation, and D&D Pharmatech. He is a Specialty Chief Editor for the Cancer Molecular Targets and Therapeutics Section of Frontiers in Oncology. He is also a Section Editor for Molecular Oncology and HemOnc Today. Dr El-Deiry is the scientific founder and shareholder of Oncoceutics, Inc. and p53-Therapeutics, Inc.
-
Eduardo Franco
McGill University, Canada
Eduardo Franco is Professor and Chairman, Department of Oncology, and Director, Division of Cancer Epidemiology, McGill University, Montreal. He holds BSc (1975) and Licentiate (1976) degrees in biology from Universidade de Campinas, Brazil, and master's (MPH) and doctoral (DrPH) degrees in public health microbiology from the University of North Carolina at Chapel Hill (1981-84). He was a Guest Researcher at the US Centers for Disease Control in Atlanta (1980-81 and 1983-84), and a post-doctoral fellow in cancer epidemiology during 1984 at the International Agency for Research on Cancer in Lyon, France, at the US National Cancer Institute (NCI) in Bethesda, and at Louisiana State University, in New Orleans. Since 1985, he has conducted epidemiologic research on the causes of cancer and on the means to prevent it or to improve patient survival. He is mostly known for his contributions to our understanding of human papillomavirus infection as the cause of cervical cancer and using this knowledge to prevent this cancer via vaccination and improved screening strategies. He received the Canadian Cancer Research Alliance’s Distinguished Service to Cancer Research Award, Lifetime Achievement Awards from the American Society for Colposcopy and Cervical Pathology and from the International Papillomavirus Society, the Women in US Government’s Leadership Award, the Canadian Cancer Society’s Warwick Prize, the Geoffrey Howe Outstanding Contribution Award from the Canadian Society for Epidemiology and Biostatistics, the University of British Columbia’s Chew Wei Memorial Prize in Cancer Research, and the McLaughlin-Gallie Award from the Royal College of Physicians of Canada. He has mentored 115 graduate students and post-doctoral fellows, and 30 undergraduate trainees. He is Officer of the Order of Canada and Fellow of the Royal Society of Canada and of the Canadian Academy of Health Sciences. Heholds an honorary doctorate from Universidade Fernando Pessoa, Porto, Portugal.
- Expertise
- Cancer Biology
- Epidemiology and Global Health
- Medicine
- Research focus
- cancer epidemiology
- cancer prevention
- human papillomavirus
- cancer screening
- Experimental organism
- human
- Competing interests statement
- Entire research program funded by the Medical Research Council of Canada (until 1999), Canadian Institutes of Health Research (CIHR) (1999-present), National Institutes of Health, Canadian Cancer Society, and Cancer Research Society. He has received salary awards from the Fonds de Recherche Quebec Santé and CIHR. He holds a James McGill Professorship and the Minda de Gunzburg Endowed Chair at McGill University. He serves as Editor-in-Chief for Preventive Medicine and Preventive Medicine Reports and serves on the editorial boards of Cancer Epidemiology, Biomarkers & Prevention, International Journal of Cancer, Papillomavirus Research, and Salud Publica de Mexico. He has served as occasional consultant to companies involved with HPV vaccination (Merck and GSK) and HPV diagnostics (Roche, Abbott, Qiagen, and BD).
-
Caigang Liu
Shengjing Hospital of China Medical University, China
Caigang Liu received his PhD from the China Medical University, and trained clinically at first hospital of China Medical University. Then joined and served as a director of Breast Center Shengjing Hospital of China Medical University in 2016. His current research interests focus on clinical and translational research of oncology. In recent years, he has led a clinical research term to explore the improvement in breast reconstruction surgery and highly safe and effective anti-cancer strategies, along with identification of therapeutic targets and development of small molecular drugs against cancer metastasis. He has led several projects funded by the National Natural Science Foundation, including the discovery of FSIP1 as a new target for anti-HER2 treatment, and is developing a new strategy to reverse anti-HER2 resistance in breast cancer. He is a member of the National Micro-noninvasive Committee of Chinese Medical Association, a vice chairman of the first breast disease branch of China Sexology Association, and a member of the Standing Committee in breast cancer marker collaboration group of Chinese Anti-cancer Association.
- Expertise
- Medicine
- Cancer Biology
- Research focus
- surgical oncology
- oncological clinical trials
- breast cancer translational medicine
- cancer metastasis and drug resistance
- small molecular drug development
- Experimental organism
- human
- mouse
- Competing interests statement
- Caigang Liu is currently funded by the National Natural Science Foundation of China and “Top young talent” project of Liaoning province, China. He now holds a number of patents for anti-tumor small molecular drugs and Traditional Chinese Medicine.
-
Tony Ng
King's College London, United Kingdom
Tony Ng (FMEDSCI, MB ChB, MRCP, FRCPath, PhD) brings a rich spectrum of knowledge and capabilities with clinical experience in treating AIDS patients (with opportunistic infections and cancers) and fundamental immunology skills. He is also a pioneer of molecular imaging in cancer. He was the first person to use antibody based fluorescence lifetime imaging (FLIM) approaches in tumour cells and tissues to monitor protein states and function. He has published on how to visualize protein biochemistry in preclinical models; as well as in patient-derived cancer tissues for establishing in vitro/ companion diagnostics. He has adopted a multidisciplinary approach to understand cancer recurrence and also to stratify molecularly targeted agents in combination with immunotherapy. His research bridges the gap between physics, biology and medicine, particularly in the field of translational cancer research.
For clinical translation, he has the proven ability to coordinate and work cooperatively with colleagues and leaders in a wide variety of disciplines (imaging, cell biology, oncology, bioinformatics, surgery, pathology, genomics, as well as physical science disciplines such as mathematics, physics, chemistry and engineering). He has directed the KCL and UCL Comprehensive Cancer Imaging Centre (CCIC, one of four centres funded by CRUK & EPSRC in the UK) since its inception in 2008. The vision for the CCIC is to develop novel imaging (PET and MRI) technologies and use them in combination with clinicopathological assessment, genomics and in-house nanoscopic imaging to measure protein interactions in the context of interventional trials. In such trial context, the tissue imaging (FLIM histology) approach he has developed and refined over the years is beginning to reveal ErbB/ HER receptor rewiring as a mechanism of resistance in human tumours under selection pressure such as cetuximab.
Tony Ng is the current Director of the Comprehensive Cancer Centre, part of the KCL School of Cancer & Pharmaceutical Sciences, and the National Institute for Health and Care Research (NIHR) Guy’s & St Thomas’ Biomedical Research Centre (BRC) Cancer Theme. In 2022, he joined GSK on a part-time basis, to help establish the GSK-KCL Translational Oncology Research Hub which was which was announced in September 2021. The aim is to apply his clinical medicine training as well as immunology, biochemistry and imaging expertise to accelerate the development of the anti-cancer drugs. HIs experience of collaborating with mathematicians/theoretical physicists creates an opportunity to bridge the biology & AI/ML interface, an essential component of delivering the innovative Digital biological twin vision.
Training/expertise: Medicine, Immunology, Cancer cell biology, Biochemistry and Optical Imaging/Biophysics as well as preclinical Radionuclide imaging.
- Expertise
- Medicine
- Cancer Biology
- Immunology and Inflammation
- Research focus
- imaging
- biomarkers
- trial
- immune
- cancer
- reverse translation
- exosome
- organoid
- tumour microenvironment
- Competing interests statement
- At KCL, Tony Ng receives funding from Cancer Research UK, Medical Research Council, Wellcome Leap Inc., European Commission and GSK. He is employed on a part time basis as the Vice President of the Digital biological twin Unit at GSK.
-
Päivi Ojala
University of Helsinki, Finland
Imperial College London, United KingdomPäivi Ojala is the Professor of Cancer Cell Biology at University of Helsinki and Chair of Viral Tumorigenesis at Imperial College London. She has made significant contributions to the Kaposi’s Sarcoma herpesvirus (KSHV) field and has more recently focused also on the role of lymphatic endothelial microenvironment on cancer cell metastasis. She has expertise in organotypic 3D co-culture models, cell-based high-content screens, protein kinase signalling and viral technologies. Her work has led to demonstration of restoration of p53 function by small molecule inhibitors as a therapeutic modality for KSHV-induced lymphomas, identification of host Pim kinases, nucleophosmin, and the p53-p21 axis as novel regulators of viral replication, and shown that KSHV infection reprograms lymphatic endothelial cells (LECs) to a new, more invasive cell type. They have also demonstrated that LEC interaction with melanoma cells leads to increased distant organ metastasis in vivo, which is dependent on MMP14, Notch3 and b1-integrin- Dr. Ojala holds a doctoral degree in Molecular Genetics from the University of Helsinki, and has received postdoctoral training at the Yale School of Medicine, CT, USA.
- Expertise
- Cancer Biology
- Microbiology and Infectious Disease
- Research focus
- human tumor viruses
- virus-host interactions
- cancer metastasis
- notch signaling
- lymphatic endothelial transcription factors
- CAR T cell therapies
- Experimental organism
- human primary and cancer cells
- immunocompromised mouse
- Competing interests statement
- Päivi Ojala receives funding from the Academy of Finland, Sigrid Juselius Foundation, Cancer Foundation Finland and University of Helsinki.
-
Lynne-Marie Postovit
University of Alberta, Canada
Dr Lynne-Marie Postovit is a Professor and Head of the Department of Biomedical and Molecular Sciences (DBMS) at Queen’s University. Prior to this she held several endowed chairs in Cancer Research at the University of Alberta. Overall, Dr Postovit’s work has yielded many fundamental discoveries, leading to highly cited papers as well as putative clinical applications. As examples, she is recognized for her work related to the role of NODAL, a stem-cell associated protein, in cancer progression, as well as significant contributions related to extracellular matrices, the role of hypoxia in cancer progression and more recently the role of mRNA translation in cancer cell plasticity. Her discoveries have also provided the foundations for three patents. While focused on fundamental biology related to cancer cell plasticity, Dr Postovit’s research has often been translated to the clinic, for the benefit of patients.
Exemplifying her stature in the field, Dr Postovit has served on the editorial boards of journals and has presented her work at international conferences and institutions around the globe. Dr Postovit’s achievements have also been recognized by invitations to participate on scientific advisory boards, adjudication panels, and planning committees. For instance, she was a member of the Standing Committee on Research Excellence [Terry Fox Research Institute (TFRI)], the Scientific Advisory Board for the Cancer Research Society, the AACR Regional Advisory Subcommittee of Canada, and the Medical Review panel (Gairdner Foundation). These boards decided the outcomes of some of the most prestigious awards and grants related to cancer research. Dr Postovit has also received several awards and accolades: For example, she was the top ranked New Investigator at the CIHR (2009) and in 2016, was nominated to the college of the Royal Society of Canada.
Importantly, Dr Postovit has been a dedicated advocate for the research enterprise at large. She was a founding co-director of the Cancer Research Institute of Northern Alberta, wherein she built educational programming and organizational structures to support translational cancer research. More recently she has been building core research capacities at Queen’s, obtaining funds from sources such as the Transformative Educational Research Fund, to establish team based experiential learning opportunities in the health sciences and to ensure equitable access to research infrastructure.
- Expertise
- Cancer Biology
- Cell Biology
- Stem Cells and Regenerative Medicine
- Research focus
- cellular plasticity
- tumour microenvironment
- hypoxia
- stem cells
- metastasis
- ovarian cancer
- breast cancer
- Competing interests statement
- Dr Postovit holds funding from the Canadian Institutes of Health Research, the Cancer Research Society, the Canadian Cancer Society and the Canadian Foundation for Innovation.
-
Richard M White
Ludwig Institute for Cancer Research, University of Oxford, United Kingdom
Richard White, M.D., Ph.D, is a physician-scientist at the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. He is interested in basic mechanisms underlying metastasis, using the zebrafish as a model system. His work has established numerous techniques for cancer modeling and high-resolution imaging in the fish. Using these tools, the lab is focused on the cross-talk between tumor cells and the microenvironment, and how this interplay influences metastatic success. His work has revealed novel interactions between melanoma cells and adipocytes in the microenvironment, and how neural crest programs play roles in melanoma progression. He has been awarded the NIH Director’s New Innovator Award, the Pershing Square Foundation Award, and the Mark Foundation ASPIRE award.
- Expertise
- Cancer Biology
- Cell Biology
- Developmental Biology
- Medicine
- Research focus
- development
- neural crest
- zebrafish
- cancer
- melanoma
- metastasis
- microenvironment
- Experimental organism
- zebrafish
- Competing interests statement
- Richard White receives funding from the National Institutes of Health, the Pershing Square Sohn Foundation, the Mark Foundation, the Melanoma Research Alliance, the American Cancer Society and the Harry J. Lloyd Foundation. He receives consulting fees from N-of-One, Inc.
Reviewing editors
-
Nicola Aceto
Swiss Federal Institute of Technology in Zurich, Switzerland
- Expertise
- Cancer Biology
- Research focus
- disseminated tumor cells
- circulating tumor cells
- cancer progression
- metastasis
-
Sameh Ali
Children's Cancer Hospital Egypt, Egypt
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Cell Biology
- Immunology and Inflammation
- Neuroscience
- Structural Biology and Molecular Biophysics
- Research focus
- metabolism
- mitochondria
- redox biology
- reactive oxygen species
- membrane biophysics
- inflammation
- aging
- oncology
-
Wadih Arap
Rutgers Cancer Institute of New Jersey at University Hospital, United States
- Expertise
- Medicine
- Cancer Biology
- Research focus
- clinical oncology
- genitourinary (GU) cancers
- prostate cancer
-
Robert Baiocchi
The Ohio State University, United States
- Expertise
- Medicine
- Cancer Biology
- Immunology and Inflammation
- Research focus
- Epstein Barr Virus
- lymphoma
- cancer therapeutics
- cancer vaccines
- cancer immunology
- cancer immunotherapy
- cancer epigenetics
-
Paul R Barber
King's College London, United Kingdom
- Expertise
- Cancer Biology
- Research focus
- machine learning
- microscopy
- biostatistics
- multi-modal predictive models
- fluorescence lifetime microscopy
-
Frederic A Bard
Institute of Molecular and Cell Biology (A*STAR), Singapore
- Expertise
- Cell Biology
- Cancer Biology
- Research focus
- Golgi
- protein glycosylation
- signaling
- cancer
- matrix degradation
- cell migration
- Experimental organism
- human
- mouse
-
Pedro Batista
National Institutes of Health, National Cancer Institute, United States
- Expertise
- Cancer Biology
- Chromosomes and Gene Expression
- Research focus
- RNA modifications
- tRNA
- RNA demethylases
- m6A
- mRNA processing
-
Anton M Bennett
Yale University, United States
- Expertise
- Cell Biology
- Biochemistry and Chemical Biology
- Cancer Biology
- Research focus
- cell signalling
- metabolism
- protein tyrosine phosphorylation
- protein tyrosine kinases
- protein tyrosine phosphatases
-
Philip Boonstra
University of Michigan, United States
- Expertise
- Medicine
- Epidemiology and Global Health
- Cancer Biology
- Genetics and Genomics
- Research focus
- biostatistics
- clinical trials
- cancer biostatistics
- epidemiology
- ECMO
- statistical programming
-
Jungmin Choi
Korea University College of Medicine, South Korea
- Expertise
- Cancer Biology
- Computational and Systems Biology
- Genetics and Genomics
- Medicine
- Research focus
- rare disorders
- single cell genomics
- computational biology
- human genomics
-
Seth J Corey
Cleveland Clinic, United States
- Expertise
- Cancer Biology
- Medicine
- Research focus
- myeloid malignancies
- inherited or acquired bone marrow failure
- neutrophils
- platelets zebrafish
- cancer evolution
- proteostasis
-
Jose Renato Rosa Cussiol
Federal University of São Paulo, Brazil
- Expertise
- Biochemistry and Chemical Biology
- Cell Biology
- Cancer Biology
- Genetics and Genomics
- Chromosomes and Gene Expression
- Research focus
- DNA damage response
- yeast genetics
- DNA damage signaling
- genomic instability
- inositol metabolism
- inositol polyphosphate pathway
-
Maximiliano A D'Angelo
Sanford Burnham Prebys Medical Discovery Institute, United States
- Expertise
- Cancer Biology
- Cell Biology
- Immunology and Inflammation
- Research focus
- nuclear pore complex
- nuclear transport
- importin
- exportin
- immunology
- cancer
- muscle
-
Yunlu Dai
University of Macau, Macao SAR China
- Expertise
- Cancer Biology
- Immunology and Inflammation
- Stem Cells and Regenerative Medicine
- Research focus
- cancer immunotherapy
- drug delivery
- biomaterials
- ferroptosis
- breast cancer
- cancer
- metal ions
-
Irwin Davidson
Institut de Genetique et de Biologie Moleculaire et Cellulaire, CNRS/INSERM/UDS, France
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Chromosomes and Gene Expression
- Research focus
- transcription
- chromatin
- genomics
- cancer
- Experimental organism
- human
- mouse
-
Martin Eilers
University of Würzburg, Germany
- Expertise
- Cancer Biology
- Research focus
- Myc proteins
- Myc function
- Targeting N-MYC/AURORA for tumor therapy
- Myc and Ubiquitin
- Experimental organism
- human
-
Rachel Evans
King's College London, United Kingdom
- Expertise
- Cancer Biology
- Immunology and Inflammation
- Research focus
- macrophages
- lymphangiogenesis
- angiogenesis
- microenvironment
- breast cancer
- metastasis
-
Eduardo Eyras
Australian National University, Australia
- Expertise
- Genetics and Genomics
- Cancer Biology
- Chromosomes and Gene Expression
- Computational and Systems Biology
- Research focus
- bioinformatics
- transcriptomics
- long-read sequencing technologies
- RNA splicing
- alternative splicing
- nanopore
-
Yvonne Fondufe-Mittendorf
Van Andel Institute, United States
- Expertise
- Genetics and Genomics
- Chromosomes and Gene Expression
- Cancer Biology
- Research focus
- gene expression
- chromatin biology
- toxicology
- RNA biology
- nucleosome structure
-
Arun K Ganesan
University of New Mexico, United States
- Expertise
- Cancer Biology
- Chromosomes and Gene Expression
- Research focus
- epigenetic regulation
- chromatin biology
- RNA-chromatin interactions
- LncRNA
-
Ilias Georgakopoulos-Soares
Pennsylvania State University, United States
- Expertise
- Cancer Biology
- Computational and Systems Biology
- Genetics and Genomics
- Research focus
- proteomics
- genomics
- bioinformatics
- biomarkers
- machine learning
-
Yogesh K Gupta
The University of Texas Health Science Center at San Antonio, United States
- Expertise
- Medicine
- Structural Biology and Molecular Biophysics
- Cancer Biology
- Microbiology and Infectious Disease
- Research focus
- drug discovery
- nucleic acid modifications
- cancer epigenetics
- structures of viral proteins
- host-pathogen interactions
-
Elizabeth P Henske
Brigham And Women's Hospital, United States
- Expertise
- Medicine
- Cancer Biology
- Research focus
- tuberous sclerosis complex
- lymphangioleiomyomatosis
- mTOR
- prostate cancer
-
Ping-Chih Ho
Ludwig Institute for Cancer Research, Switzerland
- Expertise
- Cancer Biology
- Immunology and Inflammation
- Cell Biology
- Research focus
- immunometabolism
- cancer immunology
- tumor microenvironment
- immunotherapy
- adaptive immunity
- macrophages
- metabolic disease
- Experimental organism
- mouse
-
Wenwei Hu
Rutgers University, United States
- Expertise
- Cancer Biology
- Research focus
- p53 signaling
- tumor suppressors
- cancer metabolism
- cancer cell biology
- signal transduction
- Experimental organism
- human
- mouse
-
Tony Hunter
Salk Institute for Biological Studies, United States
- Expertise
- Cancer Biology
- Cell Biology
- Research focus
- cancer
- signal transduction
- phosphorylation
- ubiquitylation
- sumoylation
- Experimental organism
- mouse
- yeast
-
Arezu Jahani-Asl
McGill University, Canada
- Expertise
- Cancer Biology
- Cell Biology
- Developmental Biology
- Research focus
- glioblastoma
- stem cells
- mitochondria
- transcription
- mental retardation
- neurodegeneration
- cancer
- Experimental organism
- mouse
-
Jae-Wook Jeong
University of Missouri – Columbia, United States
- Expertise
- Medicine
- Cancer Biology
- Research focus
- estrogen
- endometriosis
- uterus
- endometrium
- endometrial cancer
- implantation
- decidualization
- progesterone
-
Jean Jiang
The University of Texas Health Science Center at San Antonio, United States
- Expertise
- Medicine
- Cell Biology
- Cancer Biology
- Research focus
- gap junctions
- hemichannels
- connexins
- bone biology
- osteocyte
- bone mechanobiology
- cancer bone metastasis
- lens biology
-
Omowumi Kayode
Mountain Top University, Nigeria
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Cell Biology
- Immunology and Inflammation
- Medicine
- Research focus
- biochemistry
- nutrition
- cancer
- male sexual function
- reproductive tissues
-
Anand Krishnan
University of the Free State, South Africa
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Immunology and Inflammation
- Stem Cells and Regenerative Medicine
- Research focus
- molecular medicine
- nanotoxicology
- chemical pathology
- extracellular vesicles
-
Tapas K Kundu
Jawaharlal Nehru Centre for Advanced Scientific Research, India
- Expertise
- Cancer Biology
- Chromosomes and Gene Expression
- Biochemistry and Chemical Biology
- Research focus
- epigenetics
- chromatin organization
- nonhistone chromatin proteins
- epigenetic regulation of diseases
- eukaryotic transcription regulation
- small molecule modulators of epigenetic enzymes
- Experimental organism
- human
- mouse
-
Ashish Lal
National Institutes of Health, United States
- Expertise
- Cancer Biology
- Biochemistry and Chemical Biology
- Chromosomes and Gene Expression
- Genetics and Genomics
- Research focus
- RNA biology
- lncRNAs
- microRNAs
- gene regulation
- cancer biology
- p53
- Experimental organism
- human
-
Emmanuel Lamptey
KAAF University College, Ghana
- Expertise
- Cancer Biology
- Epidemiology and Global Health
- Immunology and Inflammation
- Medicine
- Research focus
- health literacy
- health communication
- health promotion
- health education
- patient education
- chronic diseases
- geriatric assessment
- neoplasm
-
Beate Lichtenberger
Medical University of Vienna, Austria
- Expertise
- Cancer Biology
- Stem Cells and Regenerative Medicine
- Research focus
- Cancer-associated fibroblasts (CAFs)
- fibroblast-mediated skin pathologies
- skin cancer
- stem cell fate decisions
- Experimental organism
- human
- mouse
-
Huiping Liu
Northwestern University, United States
- Expertise
- Medicine
- Cancer Biology
- Research focus
- cancer stem cells
- circulating tumor cells
- exosome
- cancer immunity
- metastasis
- breast cancer
-
Kay F Macleod
University of Chicago, United States
- Expertise
- Cell Biology
- Cancer Biology
- Research focus
- autophagy
- mitochondria
- pancreatic cancer
- breast cancer
- liver homeostasis
- tumor metabolism
- Experimental organism
- mouse
- human
-
Simón Méndez-Ferrer
University of Cambridge, United Kingdom
- Expertise
- Stem Cells and Regenerative Medicine
- Developmental Biology
- Cancer Biology
- Medicine
- Research focus
- haematopoietic stem cell niche
- mesenchymal stem cells
- myeloproliferative neoplasms
- acute myeloid leukemia
- neuroimmunology
-
Salem Y Mohamed
Zagazig University, Egypt
- Expertise
- Cancer Biology
- Cell Biology
- Chromosomes and Gene Expression
- Epidemiology and Global Health
- Genetics and Genomics
- Immunology and Inflammation
- Medicine
- Microbiology and Infectious Disease
- Research focus
- advanced endoscopy
- cell biology
- cancer
- inflammation
- genetics
- basic medicine
-
Shiny Nair
Yale University, United States
- Expertise
- Medicine
- Immunology and Inflammation
- Cancer Biology
- Research focus
- immunology
- neurodegeneration
- NKT cells
- mycobacterium
- lysosomal storage disorder
-
Goutham Narla
University of Michigan, United States
- Expertise
- Medicine
- Cancer Biology
- Genetics and Genomics
- Research focus
- cancer therapeutics
- cancer genetics
- small molecule drug development
- protein phosphatase
- Experimental organism
- human
- mouse
-
Izuchukwu Okafor
Nnamdi Azikiwe University, Nigeria
- Expertise
- Cancer Biology
- Cell Biology
- Chromosomes and Gene Expression
- Developmental Biology
- Epidemiology and Global Health
- Genetics and Genomics
- Medicine
- Neuroscience
- Research focus
- developmental biology
- reproductive biology
- gene expression
- molecular biology
- public health
- reproductive health
- medical education
- anatomical sciences
- neuroreproduction
-
Anna Panchenko
Queen's University, Canada
- Expertise
- Chromosomes and Gene Expression
- Computational and Systems Biology
- Cancer Biology
- Research focus
- molecular modeling
- bioinformatics
- machine learning
- molecular dynamics simulations
- cancer mutations
- chromosome and nucleosome dynamics
-
Renata Pasqualini
Rutgers University, United States
- Expertise
- Medicine
- Cancer Biology
- Research focus
- radiation oncology
- translational cancer research
- prostate cancer
- vascular biology
-
Laura Rogers
Mayo Clinic, United States
- Expertise
- Cancer Biology
- Cell Biology
- Immunology and Inflammation
- Research focus
- T cells
- immunotherapy
- sleeping beauty
- functional genomics
- mouse models of cancer
- tumor microenvironment
-
Natalia Rubinstein
University of Buenos Aires-CONICET, Argentina
- Expertise
- Cancer Biology
- Immunology and Inflammation
- Medicine
- Stem Cells and Regenerative Medicine
- Research focus
- breast cancer tumor cell
- molecular biology
- drug resistance
- tumor immunology
-
Alejandro San Martín
Centro de Estudios Científicos and Universidad San Sebastián, Chile
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Cell Biology
- Research focus
- imaging
- metabolism
- FRET
- single-fluorophore
- single-cell
- cell physiology
- optogenetics
-
Charles Sawyers
Memorial Sloan-Kettering Cancer Center, United States
- Expertise
- Cancer Biology
- Medicine
- Research focus
- translational medicine
- oncology
- Experimental organism
- human
-
Jawed Siddiqui
University of Nebraska Medical Center, United States
- Expertise
- Medicine
- Cancer Biology
- Research focus
- bone metastasis
- cancer metastasis
- chemokines
- osteoclasts
- osteoblasts
- tumor dormancy
- therapeutic
-
Kumaravel Somasundaram
Indian Institute of Science Bangalore, India
- Expertise
- Cell Biology
- Medicine
- Cancer Biology
- Genetics and Genomics
- Chromosomes and Gene Expression
- Research focus
- cell signalling
- glioma
- gene regulation
- cancer therapeutics
- cancer genomics
- cancer stem cells
- non-coding RNA
- chemoresistance
-
Margaret Stanley
University of Cambridge, United Kingdom
- Expertise
- Cancer Biology
- Microbiology and Infectious Disease
- Medicine
- Epidemiology and Global Health
- Research focus
- vaccines
- cervix cancer
- cervix precancer
- keratinocyte biology
- human papillomavirus
- DNA viruses
- vaccine immunology
- Experimental organism
- human
-
Ivan Topisirovic
Jewish General Hospital, Canada
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Cell Biology
- Research focus
- mRNA translation
- signaling
- metabolic regulation
- protein quality control
- Experimental organism
- mouse
- human
-
Jia Wei
Clinical Cancer Institute of Nanjing University, China
- Expertise
- Cancer Biology
- Immunology and Inflammation
- Research focus
- cancer immunotherapy
- immune evasion
- tumor immune microenvironment
- tumor neoantigen
- adoptive cell therapy
- tumor-associated macrophages
- gastric cancer
- immune checkpoints
-
Urbain Weyemi
National Cancer Institute, National Institutes of Health, United States
- Expertise
- Cancer Biology
- Research focus
- cancer metabolism
- genomic stability
- redox biology
- reactive oxygen species
- cancer therapy
- mitochondrial homeostasis
-
Jian Xu
St. Jude Children's Research Hospital, United States
- Expertise
- Cancer Biology
- Chromosomes and Gene Expression
- Developmental Biology
- Genetics and Genomics
- Stem Cells and Regenerative Medicine
- Research focus
- hematopoiesis
- erythropoiesis
- myeloid leukemia
- epigenetics
- transcription regulation
- enhancer
- metabolism
- Experimental organism
- human
- mouse
-
Yongliang Yang
Dalian University of Technology, China
- Expertise
- Medicine
- Cancer Biology
- Computational and Systems Biology
- Research focus
- bioinformatics
- computational biology
- drug discovery
- artificial intelligence
-
Norma Ybarra
Research Institute McGill University Health Center, Canada
- Expertise
- Cancer Biology
- Stem Cells and Regenerative Medicine
- Research focus
- radiation biology
- radiotherapy
- cancer cell metabolism
- cancer therapies
-
Keqiang Ye
Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, China
- Expertise
- Medicine
- Cancer Biology
- Biochemistry and Chemical Biology
- Neuroscience
- Research focus
- neuroscience
- molecular cytobiology
- cancer biology
- neurodegenerative disease
- Experimental organism
- mouse
-
Neeha Zaidi
Johns Hopkins University, United States
- Expertise
- Cancer Biology
- Immunology and Inflammation
- Medicine
- Research focus
- immunology
- immunotherapy
- vaccines
- cancer
- cancer immunology
- clinical trials
- translational research
- T cell biology
-
Samir Zaidi
Memorial Sloan Kettering Cancer Center, United States
- Expertise
- Cancer Biology
- Computational and Systems Biology
- Medicine
- Research focus
- genetically engineered mouse models
- computational genomics
- single cell genomics
- organoids
- drug resistance
- cancer cell plasticity
-
Qing Zhang
University of Texas Southwestern Medical Center, United States
- Expertise
- Cancer Biology
- Biochemistry and Chemical Biology
- Research focus
- CRISPR
- cancer metabolism
- hypoxia
- kidney cancer
- breast cancer
- epigenetics
- post-translational modifications
- synthetic lethality
-
Zhiguo Zhang
Columbia University Medical Center, United States
- Expertise
- Chromosomes and Gene Expression
- Cancer Biology
- Research focus
- epigenetic inheritance
- chromatin
- DNA replication
- brain tumors
- histone chaperones
- histone modifications
- oncohistone mutations
- epigenomes
-
Yu Zhao
Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, China
- Expertise
- Biochemistry and Chemical Biology
- Cancer Biology
- Chromosomes and Gene Expression
- Genetics and Genomics
- Research focus
- prostate cancer
- noncoding RNA
- m6A
- epigenetics
- enhancer
- DNA damage
- senescence
- radiotherapy
-
Shengtao Zhou
Sichuan University West China Second University Hospital, China
- Expertise
- Cancer Biology
- Medicine
- Research focus
- gynecologic oncology
- cancer biology
- tumor immunology
- metabolism
- nuclear receptors
- systems biology
- Experimental organism
- human
- mouse
-
Hao Zhu
University of Texas Southwestern Medical Center, United States
- Expertise
- Cancer Biology
- Stem Cells and Regenerative Medicine
- Medicine
- Research focus
- mechanisms of tissue repair and organ regeneration
- liver cancer
- hepatocellular carcinoma
- epigenetics
- polyploidy
- Experimental organism
- human
- mouse